THERAPY DOSSIER · th-e8f30831d77f

XJB-5-131

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32796819 ↗2020Reported benefit

XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemia-reperfusion injury.

MouseIschaemia-reperfusionRenalC57BL/6MaleIntraperitoneal10 mg/kg30 minutes before ischaemia, then daily for 3 days after surgery

Model: Unilateral renal ischaemia-reperfusion injury with 30 minutes of renal artery clamping

XJB-5-131 attenuated ischaemia-reperfusion renal injury and inflammation by inhibiting ferroptosis rather than necroptosis or pyroptosis.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…